Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma

BACKGROUND: Daratumumab (Dara), an anti‐CD38 monoclonal antibody, has an immunologic mechanism of action through targeting of CD38 expressing immune cells in patients with multiple myeloma (MM). Furthermore, it was recently shown that CD38 upregulation in tumors, is a major mechanism of acquired res...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Med
Hlavní autoři: Stocker, Nicolas, Gaugler, Béatrice, Ricard, Laure, de Vassoigne, Frédéric, Marjanovic, Zora, Mohty, Mohamad, Malard, Florent
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Clinical Cancer Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7064026/
https://ncbi.nlm.nih.gov/pubmed/31991058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2827
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky